NIHR Doctoral Fellow @IP_London @NIHRresearch | Urology registrar @NorthLonUrol | @Packers owner | 🇬🇧🇲🇾🇨🇳
London, England
Joined December 2017
- Tweets2.9K
- Following3K
- Followers2.1K
- Likes10.6K
Pinned Tweet
A career highlight to lead this study on 10 year outcomes in almost 3500 men undergoing focal therapy, now published in @EUplatinum
And fantastic to see the widespread UK media coverage today across TV, radio, and print!
Many thanks to my collaborators and mentors 🙏
🚨 NEW IN @EUplatinum! 🚨
The largest analysis of focal therapy by Imperial Prostate and UK colleagues, reporting 1⃣0⃣-year outcomes after focal HIFU and cryotherapy in 3⃣4⃣7⃣7⃣ men 🔥🧊
Led by @AJWLight @LondonProstate1 @TaimurShah
Read for free: europeanurology.com/article/…
Alexander Light retweeted
The #RADAR Study is now open!🚨
High risk men aged 40-49 will have a #Prostagram scan, a Stockholm3 test, and a PSA test to find the best way to screen for #ProstateCancer. Check if you can sign up here: imperial.eu.qualtrics.com/jf…
@NIHRresearch @ImperialSandC @ImperialNHS
Alexander Light retweeted
Absolutely delighted to launch the #RADAR study at @ImperialNHS to #screen younger, but higher risk men for #ProstateCancer. All men get 3 advanced tests on the same day - express your interest here: imperial.eu.qualtrics.com/jf…
@LondonProstate1 @IP_London @NIHRresearch
Alexander Light retweeted
Delighted to share our newly published PART trial protocol paper bjui-journals.onlinelibrary.… #focaltherapy #prostatecancer @NDSurgicalSci @SITU_Oxford @NIHRresearch @QuinteTBristol @PART_Trial @BJUIjournal We continue at pace to deliver high level evidence in the field
Interesting
TARGET international consensus guidance - we had uncertainty as to whether the pre-treatment MRI needs DCE (Eur Urol 2024; europeanurology.com/article/…)
But PI-FAB, published by the same institution as PRIME, requires comparison with the pre-treatment DCE images 🤷
Great point-counterpoint at the podium today: @veerukasi arguing biparametric MRI should be the new standard of care for prostate cancer diagnosis vs @RaisBahrami making the case to keep contrast. PRIME (JAMA 2025) says bpMRI is noninferior to mpMRI for csPCa (29.0% vs 29.6%, 555 men, 22 centers). Shorter scan, no gadolinium. The counterargument: DCE still helps with equivocal PI-RADS 3 lesions and better defines lesion size, which matters for focal therapy planning. Where do you land? @FocalSociety @Endo_Society #ProstateCancer #bpMRI #PRIMEtrial #FTS2026 @JAMA_current
Alexander Light retweeted
New milestone reached!
IP10-AVIDITY has now recruited over 50 patients.
Congratulations to @royalmarsdenNHS for recruiting the 50th patient 👏
Alexander Light retweeted
PSA to all my urologic cancer colleagues. Stop personally treating PCa. We should refer all prostate pts to @EvanThomas84. His outcomes are "perfect." NEVER has had a patient with urinary issues after prostate radiation. In fact they have better function.
Do you know why?
Because I care about my men’s post treatment QOL, and their urinary and sexual function is medically optimized before I start treatment.
Everyone gets a PDE5 inhibitor, LUTS optimization, and either a cox inhibitor or dex through treatment.
So yes, my men’s IPSS and SHIM typically go up after I meet them, and then stay that way through treatment.
And I have NEVER left a man in pads, whether in my time in academia or since I opened a freestanding.
Curious if you can say the same.
Alexander Light retweeted
Radiation oncologists against any other treatment option: "We need data!". "Urologists are charlatans and bad surgeons!". Also their rebuttals include anecdotal comments about their overflowing clinics filled with endless focal therapy disasters.
If I had a nickel for every time a friend asked me about prostate focal therapy, I’d be rich.
I’ve personally managed 20–30 intraprostatic failures after focal therapy. One patient ended up with a permanent Foley after salvage RT. Nearly all required medical castration, which many likely could have avoided with definitive therapy upfront. The downstream consequences are real.
Our group ultimately decided not to offer focal therapy outside of very niche scenarios (for example select reirradiation not ideal for partial or full gland SBRT). If I were a patient, I might assume focal therapy is better than standard options too. The marketing is that good. #OncTwitter
Alexander Light retweeted
We have just read a Letter to the Editor from @nickva1, @alison_tree, @piet_ost that carries an implication of dishonesty, and unfaith, deliberately distorting the facts in order to criticize and mislead readers to truly understand the article .
“Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries”
We firmly oppose their behavior. Our forthcoming analysis will clarify the actual content and specifically identify how they have twisted the information.
@LondonProstate1 ,@AJWLight @IP_London
Please see our letter @alison_tree @piet_ost in response to the recent Focal therapy paper in @EUplatinum
authors.elsevier.com/a/1nlq2…
@LondonProstate1 @mrsprostate @taimurShah @ASTRO_org @ESTRO_RT
Alexander Light retweeted
Never and always are two words that should not be used in discussions with patients. I'll await your published 12-15 year oncologic and functional outcome from your personal prostate cancer panel showing 100%cancer control, 0%BCR and improved IPSS and SHIMs
Alexander Light retweeted
🎉 Delighted to welcome Sunderland Royal Hospital (@mccrackenstuart, Fraser Barbour) & @FreemanHospital (@rajan_vpillay, James Leighton) to #IP16SCOPE, an international service evaluation on #ActiveSurveillance in #ProstateCancer!
📩Interested? Email us: [email protected]
Alexander Light retweeted
🚨NEW PUBLICATION🚨
IB1-LASERCOMPLETE live in @BJUIjournal!
@TUF funded prospective feasibility study in bladder cancer:
👉 Can FCM help detrusor muscle detection in TURBT samples
📄 Read it free: doi.org/10.1111/bju.70395
Thank you to the funder, all co-authors and the patients!
Alexander Light retweeted
@Archana_GK1 presented RAPID 5-year #ActiveSurveillance outcomes at @SGU2026 in St Gallen
➡️ ~50% treatment within 5 years, GG2>GG1
➡️ Treatment triggers are heterogenous
➡️ Active surveillance needs improvement
➡️ IP9-ATLAS RCT recruiting (MRI-guided vs NICE SOC surveillance)
Alexander Light retweeted
Great presentation of the #IB1LASERCOMPLETE results looking at #FCM for detrusor muscle detection in TURBT samples by @Archana_GK1 at #SGU2026 (St Gallen)
✅ 100% feasible to interpret FCM images
✅ High inter-observer agreement
🔍 Exploratory diagnostic performance unclear
Alexander Light retweeted
📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled “Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway”.
👏 Congratulations to Chase Ng, Alexander Light, and Taimur Shah on this excellent contribution, together with all co-authors.
🔗 Read the full article here:
👉 buff.ly/vMzTvKo
#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology
Wholeheartedly recommend applying!!
📣 Calling all aspiring academic urologists: we are hiring!
Applications open soon for the 2027 @NIHRresearch Academic Clinical Fellowship in urology.
Join our 🌍-leading #ProstateCancer research group led by @LondonProstate1 💫
imperial.ac.uk/medicine/stud…
Alexander Light retweeted
Presumably SBRT for localised favourable intermediate PCa will be rolled back following this RCT of 698 patients randomised in 136 international centres; designed and powered a priori as superiority of cancer control for SBRT over MH-IMRT, but wasn’t?
jamanetwork.com/journals/jam…
🚨 5 fractions vs 20–28 fractions in intermediate-risk prostate cancer: NRG-GU005
Phase 3 RCT, 698 patients:
SBRT 36.25 Gy/5 fx vs MH-IMRT 60 Gy/20 fx or 70 Gy/28 fx.
📊 Key results
• 3-y DFS: 88.6% vs 92.1% with SBRT vs MH-IMRT
• SBRT was not superior for DFS
• Biochemical failure was higher with SBRT
• Bowel QoL decline at 2 y: 34.9% vs 43.8%, favoring SBRT
• Grade 3–4 GU toxicity: 0.6% vs 2.5%, favoring SBRT
💡 Why it matters
SBRT offers major convenience and somewhat better QoL/toxicity, but this modest-dose 5-fraction regimen did not improve cancer control.
⚠️ The DFS difference was not statistically significant after covariate adjustment, but PSA failure was higher with SBRT.
🩺 Clinical verdict: PROMISING FOR CONVENIENCE, BUT DO NOT ASSUME EQUIVALENT DOSE INTENSITY
@ASCO @oncoalert
#ProstateCancer #RadiationOncology #SBRT
Fantastic trial that will provide definitive evidence for bpMRI vs mpMRI, and fusion versus cognitive biopsy!
#IP7 #PACIFIC has recruited its 2️⃣0️⃣0️⃣0️⃣th patient! Well done to all sites involved, and to Southend @MSEHospitals who recruited patient number 2000!
Not long to go!
Alexander Light retweeted
📣Congratulations to Nikhil Mayor! Former Academic Clinical Fellow in Urology, currently Transform study’s Clinical Research Fellow and now an NIHR Doctoral Fellow with £0.5M awarded to him
🎉Amazing achievement!!
Congratulations to @NikhilMayor who has been awarded a prestigious and highly competitive @NIHRresearch Doctoral Fellowship!
The £500k award provides an opportunity to optimise screening pathways using MRI - including a #ProstateCancer screening study called #RADAR, coming soon!
Alexander Light retweeted
Congratulations to @NikhilMayor who has been awarded a prestigious and highly competitive @NIHRresearch Doctoral Fellowship!
The £500k award provides an opportunity to optimise screening pathways using MRI - including a #ProstateCancer screening study called #RADAR, coming soon!
Alexander Light retweeted
Congratulations to @AJWLight and colleagues on this outstanding @EUplatinum publication! Great to see these important findings also featured today by Argentina’s leading newspaper, @LANACION . 🇦🇷
lanacion.com.ar/sociedad/con…
@LondonProstate1 @TaimurShah
